Interestingly, the presence of mature tertiary lymphoid structures (TLSs) was recently shown to be associated with improved objective response rates, progression-free survival, and overall survival in a retrospective analysis of three independent cohorts of patients with cancer who were treated with anti-PD-1 or anti-PD-L1 antibodies, independent of PD-L1 expression status and CD8+ T cell density [30]. Here, CD274 is linked to cancer.